These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37031076)
21. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Keating NL; O'Malley AJ; Smith MR J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113 [TBL] [Abstract][Full Text] [Related]
22. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?]. Merseburger AS; Sedding D; Hüter K Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324 [TBL] [Abstract][Full Text] [Related]
23. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883 [TBL] [Abstract][Full Text] [Related]
24. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study. Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK J Clin Oncol; 2017 Nov; 35(32):3697-3705. PubMed ID: 28968166 [TBL] [Abstract][Full Text] [Related]
25. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis. Gu L; Li X; Liu W Front Endocrinol (Lausanne); 2023; 14():1157857. PubMed ID: 37065739 [TBL] [Abstract][Full Text] [Related]
26. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. Thomsen FB; Sandin F; Garmo H; Lissbrant IF; Ahlgren G; Van Hemelrijck M; Adolfsson J; Robinson D; Stattin P Eur Urol; 2017 Dec; 72(6):920-928. PubMed ID: 28711383 [TBL] [Abstract][Full Text] [Related]
27. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. Davey P; Kirby MG World J Urol; 2021 Feb; 39(2):307-315. PubMed ID: 32979057 [TBL] [Abstract][Full Text] [Related]
28. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes. Lin E; Garmo H; Van Hemelrijck M; Zethelius B; Stattin P; Hagström E; Adolfsson J; Crawley D JAMA Netw Open; 2022 Aug; 5(8):e2225600. PubMed ID: 35939302 [TBL] [Abstract][Full Text] [Related]
29. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer. Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Lopes RD; Higano CS; Slovin SF; Nelson AJ; Bigelow R; Sørensen PS; Melloni C; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Clarke NW; Olesen TK; Doyle-Olsen BT; Kristensen H; Arney L; Roe MT; Alexander JH; Circulation; 2021 Oct; 144(16):1295-1307. PubMed ID: 34459214 [TBL] [Abstract][Full Text] [Related]
31. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. Greiman AK; Keane TE Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429 [TBL] [Abstract][Full Text] [Related]
32. Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Teoh JY; Chan SY; Chiu PK; Poon DM; Cheung HY; Hou SS; Ng CF Asian J Androl; 2015; 17(3):493-6. PubMed ID: 25578930 [TBL] [Abstract][Full Text] [Related]
33. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases. George G; Garmo H; Scailteux LM; Balusson F; De Coster G; De Schutter H; Kuiper JG; Oger E; Verbeeck J; Van Hemelrijck M Int J Cancer; 2021 May; 148(9):2203-2211. PubMed ID: 33186481 [TBL] [Abstract][Full Text] [Related]
34. Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer. Lifshitz K; Ber Y; Shenhar C; Nillson J; Peer A; Rosenbaum E; Baniel J; Kedar D; Ben Zadok OI; Margel D J Urol; 2021 Oct; 206(4):952-959. PubMed ID: 34032505 [TBL] [Abstract][Full Text] [Related]
39. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110 [TBL] [Abstract][Full Text] [Related]
40. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. Conteduca V; Di Lorenzo G; Tartarone A; Aieta M Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]